Progestagen therapy for recurrent miscarriage.
BACKGROUND
Recurrent pregnancy loss (RM) affects 0.5-1% of couples. The pathophysiology of RM is complex. The suggested causes include anatomical, genetic and molecular abnormalities, endocrine disorders, thrombophilias and anti-phospholipid syndrome. In approximately 50% of the cases neither of the above can be identified. We aimed at examining the evidence on the role of progesterone in the pathophysiology of RM, and the clinical evidence on effectiveness of progestogen treatment.


METHODS
We searched PubMed and the Cochrane database covering the period of 1968-2007. The search terms progestogens and recurrent miscarriage, NK cells and recurrent miscarriage as well as cytokines and recurrent miscarriage were used.


RESULTS
Progesterone is indispensable for creating a suitable endometrial environment for implantation. RM may be due to subnormal progesterone secretion and retarded endometrial development in the peri-implantation period. Progesterone also acts on the immune system, mainly by affecting cytokine synthesis and the function of NK cells. A recent meta-analysis showed that though progesterone treatment did not affect pregnancy outcome in women with miscarriages in general, separate analysis of three small and dated studies including altogether 91 patients with RM revealed a small but significant effect. It is noteworthy that the design of these 40 years old studies does not meet modern requirements.


CONCLUSIONS
Standardized laboratory protocols for identifying potential targets of progestogen treatment as well as implementation of well-designed randomized studies are needed to establish the usefulness of progesterone supplementation in the treatment of RM.
Szekeres-Bartho
Julia
J
Department of Medical Microbiology and Immunology, Medical School, Pecs University, H-7643 Pecs, Hungary. julia.szekeres@aok.pte.hu
Balasch
Juan
J
D000026:Abortion, Habitual / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D000818:Animals; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000096:biosynthesis; D004717:Endometrium / Q000473:pathology / Q000503:physiopathology; D005260:Female; D006801:Humans; D007107:Immune System / Q000187:drug effects / Q000503:physiopathology; D007694:Killer Cells, Natural / Q000187:drug effects / Q000473:pathology; D008183:Luteal Phase; D011247:Pregnancy; D011374:Progesterone / Q000378:metabolism / Q000494:pharmacology; D011372:Progestins / Q000627:therapeutic use*
D016207:Cytokines; D011372:Progestins; D011374:Progesterone